Horizon Therapeutics plc
Horizon - Model TEPEZZA -Monoclonal Antibody
A monoclonal antibody against insulin-like growth factor-1 receptor (IGF-1R). TED in Japan (OPTIC-J): Phase 3 randomized, placebo-controlled trial in Japan to evaluate TEPEZZA in patients with moderate-to-severe active TED.
Most popular related searches
Diffuse Cutaneous Systemic Sclerosis: Phase 1 trial exploring TEPEZZA in diffuse cutaneous systemic sclerosis.
Subcutaneous Administration: Phase 1 pharmacokinetic trial to explore subcutaneous administration of TEPEZZA.
